Physician profile
Helar E Campos
NPI 1558437269
$29,431.60
in general payments reported to CMS, 2019-2025
71 companies · $5,277 in 2025
The $5,277 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,353 · 2020: $2,848 · 2021: $4,333 · 2022: $4,923 · 2023: $4,826 · 2024: $4,872 · 2025: $5,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,832.40 |
| Education | $142.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,453.56 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $3,400.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $2,220.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,658.30 | 2019-2025 | Breztri, Farxiga |
| Phathom Pharmaceuticals, INC. | $1,353.31 | 2023-2025 | Voquezna |
| Dexcom, INC. | $1,201.77 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $1,165.16 | 2019-2025 | Trintellix |
| Pfizer INC. | $1,058.95 | 2019-2025 | |
| Allergan, INC. | $992.55 | 2019-2020 | |
| Lilly USA, LLC | $804.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $724.85 | 2019-2024 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $711.77 | 2021-2025 | |
| Astellas Pharma US INC | $539.41 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $492.97 | 2019-2025 | Repatha, Otezla, Otezla |
| Ardelyx, INC. | $469.90 | 2022-2025 | Ibsrela |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helar Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.